• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝伐珠单抗给药对低氧诱导性肺动脉高压大鼠模型的影响。

Effects of bevacizumab administration on the hypoxia - induced pulmonary hypertension rat model.

机构信息

Department of Occupational Diseases, Occupational and Environmental Diseases Hospital, Ankara, Turkey.

Department of Medical Microbiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.

出版信息

Turk J Med Sci. 2021 Oct;51(5):2752-2762. doi: 10.3906/sag-2101-76. Epub 2021 Oct 21.

DOI:10.3906/sag-2101-76
PMID:34333902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8742496/
Abstract

BACKGROUND

Bevacizumab is a chemotherapeutic drug, which selectively binds to vascular endothelial growth factor (VEGF) and mainly inhibits angiogenesis and neovascularization. We aimed to study the possible effects of bevacizumab on right ventricular pressure (RVP), right ventricular hypertrophy, and VEGF, in hypoxia - induced pulmonary hypertension (PH) rat model.

METHODS

24 adult Wistar Albino rats were randomly divided into four groups: control group - saline; Bevacizumab Group; PH Group; PH + Bevacizumab Group. In hypoxia - induced model, 10% oxygen and 90% nitrogen were applied in a plexiglas box for eight days to PH Group and PH + Bevacizumab Group. On day eight, RVPs were measured directly from the heart, and then animals were sacrificed. Heart and lung tissues were examined, and Fulton index was measured.

RESULTS

RVP, Fulton index, and tissue VEGF scores were significantly lower in PH + Bevacizumab group than PH group: median (ranges), RVP, mmHg, 37.8 (33.0-39.0) and 32.3 (28.0-35.0), p: 0.01; Fulton index: 0.30 (0.29-0.33) and 0.25 (0.24-0.26), p: 0.003; tissue VEGF scores: 5.1 (4.8-5.3) and 4.0 (3.8 4.1), p: 0.004, respectively.

DISCUSSION

Bevacizumab, which is indeed an antineoplastic agent, might have a favorable effect on hypoxia - induced pulmonary hypertension.

摘要

背景

贝伐珠单抗是一种化疗药物,它选择性地与血管内皮生长因子(VEGF)结合,主要抑制血管生成和新血管形成。我们旨在研究贝伐珠单抗对缺氧诱导的肺动脉高压(PH)大鼠模型中右心室压力(RVP)、右心室肥厚和 VEGF 的可能影响。

方法

24 只成年 Wistar 白化大鼠随机分为四组:对照组-生理盐水;贝伐珠单抗组;PH 组;PH+贝伐珠单抗组。在缺氧诱导模型中,将 10%氧气和 90%氮气应用于有机玻璃箱中 8 天,使 PH 组和 PH+贝伐珠单抗组产生 PH。在第 8 天,直接从心脏测量 RVPs,然后处死动物。检查心脏和肺组织,并测量富尔顿指数。

结果

PH+贝伐珠单抗组的 RVP、富尔顿指数和组织 VEGF 评分均明显低于 PH 组:中位数(范围),RVP,mmHg,37.8(33.0-39.0)和 32.3(28.0-35.0),p:0.01;富尔顿指数:0.30(0.29-0.33)和 0.25(0.24-0.26),p:0.003;组织 VEGF 评分:5.1(4.8-5.3)和 4.0(3.8-4.1),p:0.004。

讨论

贝伐珠单抗,实际上是一种抗肿瘤药物,可能对缺氧诱导的肺动脉高压有有益的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/d36e4fe455cb/turkjmedsci-51-2752-fig007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/f453b07982cc/turkjmedsci-51-2752-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/f0db6c9c630d/turkjmedsci-51-2752-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/0fedbace95ae/turkjmedsci-51-2752-fig003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/7dca0bda0c2d/turkjmedsci-51-2752-fig004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/9fb22887829d/turkjmedsci-51-2752-fig005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/698460bb8bd8/turkjmedsci-51-2752-fig006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/d36e4fe455cb/turkjmedsci-51-2752-fig007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/f453b07982cc/turkjmedsci-51-2752-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/f0db6c9c630d/turkjmedsci-51-2752-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/0fedbace95ae/turkjmedsci-51-2752-fig003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/7dca0bda0c2d/turkjmedsci-51-2752-fig004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/9fb22887829d/turkjmedsci-51-2752-fig005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/698460bb8bd8/turkjmedsci-51-2752-fig006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea2/8742496/d36e4fe455cb/turkjmedsci-51-2752-fig007.jpg

相似文献

1
Effects of bevacizumab administration on the hypoxia - induced pulmonary hypertension rat model.贝伐珠单抗给药对低氧诱导性肺动脉高压大鼠模型的影响。
Turk J Med Sci. 2021 Oct;51(5):2752-2762. doi: 10.3906/sag-2101-76. Epub 2021 Oct 21.
2
[Hypoxia-inducible factor 1alpha regulates vascular endothelial growth factor's roles on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension].缺氧诱导因子1α对缺氧性肺动脉高压大鼠肺动脉中血管内皮生长因子作用的调控
Zhonghua Jie He He Hu Xi Za Zhi. 2004 Mar;27(3):174-8.
3
Hypoxia-inducible factor-1 alpha regulates the role of vascular endothelial growth factor on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.缺氧诱导因子-1α调节血管内皮生长因子在缺氧性肺动脉高压大鼠肺动脉中的作用。
Chin Med J (Engl). 2004 Jul;117(7):1023-8.
4
Anti-angiogenic Properties of Bevacizumab Improve Respiratory System Inflammation in Ovalbumin-Induced Rat Model of Asthma.贝伐单抗的抗血管生成特性改善卵清蛋白诱导的大鼠哮喘模型中的呼吸系统炎症。
Inflammation. 2021 Dec;44(6):2463-2475. doi: 10.1007/s10753-021-01516-w. Epub 2021 Aug 21.
5
Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia.玻璃体内注射贝伐单抗对暴露于新生儿间歇性低氧的大鼠肺血管生成生物标志物的急性和慢性影响。
Exp Lung Res. 2021 Apr;47(3):121-135. doi: 10.1080/01902148.2020.1866712. Epub 2020 Dec 30.
6
[Effect and mechanism of vascular endothelial growth factor-A on pulmonary vascular remodeling in neonatal rats with hypoxic pulmonary hypertension].血管内皮生长因子-A对新生缺氧性肺动脉高压大鼠肺血管重塑的影响及机制
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Jan;23(1):103-110. doi: 10.7499/j.issn.1008-8830.2009005.
7
The role of RNA mA methylation in the regulation of postnatal hypoxia-induced pulmonary hypertension.RNA mA 甲基化在调节产后缺氧性肺动脉高压中的作用。
Respir Res. 2021 Apr 26;22(1):121. doi: 10.1186/s12931-021-01728-6.
8
Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension.用野百合碱或低氧诱导的肺动脉高压大鼠的心肺血管内皮生长因子信使核糖核酸表达
Am J Physiol. 1998 Dec;275(6):H1948-56. doi: 10.1152/ajpheart.1998.275.6.H1948.
9
Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.丙戊酸在联合使用野百合碱和慢性低氧大鼠重度肺动脉高压模型中的治疗效果。
PLoS One. 2015 Jan 28;10(1):e0117211. doi: 10.1371/journal.pone.0117211. eCollection 2015.
10
[Effects of feixin decoction on the contents of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in the rat model of hypoxic pulmonary hypertension].肺心汤对缺氧性肺动脉高压大鼠模型中缺氧诱导因子-1α及血管内皮生长因子含量的影响
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 May;32(5):676-80.

引用本文的文献

1
Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.早产儿视网膜病变激光治疗与抗血管内皮生长因子治疗相关的肺动脉高压。
JAMA Ophthalmol. 2022 Nov 1;140(11):1085-1094. doi: 10.1001/jamaophthalmol.2022.3788.

本文引用的文献

1
Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension.血管内皮生长因子受体 2 信号的中断会引起增殖性肺血管病和肺动脉高压。
Basic Res Cardiol. 2020 Sep 3;115(6):58. doi: 10.1007/s00395-020-0811-5.
2
Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension.肺高血压啮齿动物模型中的丛状动脉病变。
Am J Pathol. 2019 Jun;189(6):1133-1144. doi: 10.1016/j.ajpath.2019.02.005. Epub 2019 Mar 26.
3
High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management.
高原性肺动脉高压:疾病发病机制与管理的最新进展
Open Cardiovasc Med J. 2016 Feb 8;10:19-27. doi: 10.2174/1874192401610010019. eCollection 2016.
4
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断与治疗工作组制定:该指南得到了欧洲儿科和先天性心脏病协会(AEPC)以及国际心肺移植学会(ISHLT)的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
5
Human high-altitude adaptation: forward genetics meets the HIF pathway.人类对高海拔的适应:正向遗传学与缺氧诱导因子(HIF)通路的交汇
Genes Dev. 2014 Oct 15;28(20):2189-204. doi: 10.1101/gad.250167.114.
6
Antiangiogenesis therapy: an update after the first decade.抗血管生成疗法:首个十年后的最新进展
Korean J Intern Med. 2014 Jan;29(1):1-11. doi: 10.3904/kjim.2014.29.1.1. Epub 2014 Jan 2.
7
Definitions and diagnosis of pulmonary hypertension.肺动脉高压的定义和诊断。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032.
8
Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.贝伐珠单抗引起的严重副作用:法国药物警戒数据库综述。
Eur J Clin Pharmacol. 2012 Jul;68(7):1103-7. doi: 10.1007/s00228-012-1232-7. Epub 2012 Feb 16.
9
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.临床医生的肺动脉高压基础科学:新概念与实验性疗法
Circulation. 2010 May 11;121(18):2045-66. doi: 10.1161/CIRCULATIONAHA.108.847707.
10
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.肺动脉高压的动物模型:病因发现与药物治疗的希望
Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32. doi: 10.1152/ajplung.00217.2009. Epub 2009 Sep 11.